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Abstract
Background: Sarcoidosis is a multisystem immuno-inflammatory disorder of unknown etiology that most
commonly involves the lungs. We hypothesized that an unbiased approach to identify pathways activated in
bronchoalveolar lavage (BAL) cells can shed light on the pathogenesis of this complex disease.
Methods: We recruited 15 patients with various stages of sarcoidosis and 12 healthy controls. All subjects
underwent bronchoscopy with lavage. For each subject, total RNA was extracted from BAL cells and hybridized to
an Affymetrix U133A microarray. Rigorous statistical methods were applied to identify differential gene expression
between subjects with sarcoidosis vs. controls. To better elucidate pathways differentially activated between these
groups, we integrated network and gene set enrichment analyses of BAL cell transcriptional profiles.
Results: Sarcoidosis patients were either non-smokers or former smokers, all had lung involvement and only two
were on systemic prednisone. Healthy controls were all non-smokers. Comparison of BAL cell gene expression
between sarcoidosis and healthy subjects revealed over 1500 differentially expressed genes. Several previously
described immune mediators, such as interferon gamma, were upregulated in the sarcoidosis subjects. Using an
integrative computational approach we constructed a modular network of over 80 gene sets that were highly
enriched in patients with sarcoidosis. Many of these pathways mapped to inflammatory and immune-related
processes including adaptive immunity, T-cell signaling, graft vs. host disease, interleukin 12, 23 and 17 signaling.
Additionally, we uncovered a close association between the proteasome machinery and adaptive immunity,
highlighting a potentially important and targetable relationship in the pathobiology of sarcoidosis.
Conclusions: BAL cells in sarcoidosis are characterized by enrichment of distinct transcriptional programs involved
in immunity and proteasomal processes. Our findings add to the growing evidence implicating alveolar resident
immune effector cells in the pathogenesis of sarcoidosis and identify specific pathways whose activation may
modulate disease progression.
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Background
Sarcoidosis is a heterogeneous disease characterized by
noncaseating granulomatous inflammation affecting mul-
tiple organs. The lung is the most common site involved in
this systemic disease with over 90 % of patients developing
pulmonary sarcoidosis [1]. Although the majority of
patients have a self-limited course, a significant subset pro-
gresses to chronic lung impairment including development
of pulmonary fibrosis and hypertension. The etiology of sar-
coidosis is unknown and its pathobiology is incompletely
understood, making treatment and management challen-
ging [2]. However, a substantial body of evidence implicates
dysregulated adaptive immune response against an un-
known inciting agent as the hallmark event in the immuno-
pathogenesis of sarcoidosis [2, 3]. In particular, aberrant
interactions between alveolar macrophages and T-helper 1
(Th1) cells in conjunction with increased Th1 and other
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cytokine levels in the airspaces are key features of pulmon-
ary sarcoidosis [3].
To our knowledge, the transcriptional state of immune
effecter cells residing within lung airspaces has not been
systematically surveyed in sarcoidosis. We hypothesized
that an unbiased approach to identify pathways differen-
tially activated in bronchoalveolar lavage (BAL) cells of sar-
coidosis patients could shed light on the pathogenesis of
this complex disease and reveal previously unrecognized
targets for future therapeutic intervention.
Methods
Study subjects
Sarcoidosis subjects (N = 25) were recruited from patients
undergoing routine clinical evaluation for diagnosis of
sarcoidosis without acute pulmonary symptoms (Table 1).
None had Löfgren’s syndrome [4]. All diagnoses were con-
firmed by pulmonary histology demonstrating non-
necrotizing granulomas in the absence of infection or
other etiologies. A healthy group (N = 12) composed of
individuals with no history of lung disease and no medica-
tion usage at time of bronchoscopy was recruited as con-
trols. These healthy individuals volunteered to undergo
bronchoscopy as part of an Institutional Review Board-
approved research program. The entire protocol was ap-
proved by the East Carolina University & Medical Center
Institutional Review Board (#05-0581) and written in-
formed consent was obtained from all participants.
Isolation of BAL cells
Briefly, three separate 50 mL aliquots of 0.89 % sterile
saline were instilled into the right middle lobe and lin-
gula for a total volume of 300 mL. Immediately on col-
lection, BAL fluid was centrifuged at 500 g for 10 min at
4 °C. The cell free supernatant was aliquoted and imme-
diately frozen at −70 °C. BAL cells were washed with
Table 1 Subject demographics and BAL cell counts
Subject Gender Age Race Smoking Stage Mac (%) Lymph (%) Pmn (%) Eos (%)
Sarc 1 M 52 AA Former 3 68 32 0 0
Sarc 2 F 32 AA Former 3 67 30 3 0
Sarc 3 F 39 AA Never 2 89 10 1 0
Sarc 4 F 61 AA Never NA 64 35 1 0
Sarc 5 M 57 AA Former 3 95 4 0 1
Sarc 6 M 68 AA Never 4 86 14 0 0
Sarc 7 F 62 AA Never 0 53 47 0 0
Sarc 8 M 34 AA Never 2 91 8 1 0
Sarc 9 F 47 AA Former 4 97 3 0 0
Sarc 10 M 48 AA Never 2 61 37 2 0
Sarc 11 F 53 C Never 2 96 4 0 0
Sarc 12 F 39 AA Never 2 70 30 0 0
Sarc 13 F 42 AA Former 1 85 15 0 0
Sarc 14 F 46 AA Never 2 67 9 24 0
Sarc 15 M 49 AA Former 2 94 5 0 1
Cont 1 M 27 AA Never — 92 5 3 0
Cont 2 M 28 AA Never — 98 2 0 0
Cont 3 F 51 C Never — 92 8 0 0
Cont 4 F 31 AA Never — 92 8 0 0
Cont 5 F 26 AA Never — 91 4 3 2
Cont 6 F 24 AA Never — 95 5 0 0
Cont 7 F 28 AA Never — 98 1 0 1
Cont 8 M 28 C Never — 98 2 0 0
Cont 9 F 26 AA Never — 98 2 0 0
Cont 10 F 27 AA Never — 97 3 0 0
Cont 11 M 30 AA Never — 95 5 0 0
Cont 12 F 35 AA Never — 93 7 0 0
Sarc sarcoidosis patient, Cont control subject, AA African American, C Caucasian, Mac macrophage, Lymph lymphocyte, Pmn polymorphonuclear cell, Eos eosinophil
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hanks balanced salt solution, resuspended and counted
with a hemocytometer. Mean viability of lavage cells
was > 95 % as determined by trypan blue dye exclusion.
Cytospin preparations were stained with a modified
wright stain for determination of differential cell counts.
Microarray experiments
Transcriptional profiling was performed on a subset of
the study cohort: 15 subjects with sarcoidosis and the 12
controls. For each subject, total RNA from BAL cells
was extracted using the RNeasy mini kit (Qiagen, Valen-
cia, CA) and its integrity verified by the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Amplified biotin-labeled cRNA was generated from
2 mg of total RNA and hybridized to Affymetrix Human
GeneChip U133A 2.0 microarrays (Affymetrix, Santa
Clara, CA) and processed according to the manufac-
turer’s instructions. Background adjustment and quantile
normalization of log-transformed intensities was per-
formed using RMA software [5]. Detailed microarray ex-
periment description, meeting Minimum Information
About a Microarray Experiment (MIAME) require-
ments, has been deposited at Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo, GSE75023).
Microarray data analysis
Initially, we used a form of multidimensional scaling
known as correspondence analysis [6] to determine
whether global variation in gene expression in BAL cells
between sarcoidosis and normal subjects would effect-
ively segregate these two groups. Next, differential gene
expression between airspace cells harvested from sar-
coidosis vs. normal controls was determined using a
Bayesian implementation of the parametric t-test [7]
coupled with false discovery (FDR) analysis [8]. An FDR
< 1 % was chosen to identify significant differential gene
expression. We performed two dimensional hierarchical
cluster analysis based on Pearson’s correlation to identify
association patterns within differentially expressed genes
and samples [9].
We applied two levels of functional enrichment analysis
to the expression dataset. First we focused on the subset
of differentially expressed genes (FDR < 1 %) and used
Webgestalt software [10] to identify over-represented
Gene Ontology categories [11]. Enrichment P-values from
this analysis were corrected for multiple testing using an
FDR threshold < 1 %. We then undertook a more unbiased
and comprehensive approach by applying Gene Set
Enrichment Analysis (GSEA) to the entire microarray
dataset using over 1300 canonical pathways derived from
multiple resources including KEGG, Reactome, Pathway
Interaction Database, and Biocarta among others [12].
These pathways have been previously curated by experts
and were available through GSEA’s molecular signature
database. An FDR < 1 % was used to designate significant
enrichment for gene sets. We used Enrichment Map [13],
an application within the Cytoscape (v3.1.1) environment,
to develop a network-based visualization of the GSEA re-
sults [14]. To display connectivity among members of spe-
cific enriched gene sets, we performed network analysis
using gene product interaction resources (Ingenuity,
STRING) and limited the relationships to experimentally
verified direct interactions [15, 16]. A schematic overview
of our approach is provided in Additional file 1: Figure S1.
qPCR validation
We confirmed differential expression of selected genes by
qPCR using the ABI Prism 7300 Detection System (Taq-
Man, Applied Biosystems, Foster City, CA). RNA from
BAL cell samples were analyzed in duplicate using primer
sets for proteasome subunit beta type 8 (PSMB8) (Cat#
PPH13734C, Qiagen, Valencia, CA), proteasome subunit
beta type 9 (PSMB9) (Cat# PPH13734C, Qiagen) and
interferon gamma (IFNG) (Cat# PPH00380C, Qiagen).
Threshold cycle (CT) values for genes of interest were nor-
malized to a housekeeping gene, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), as previously de-
scribed [17] and relative expression was calculated using
the delta-delta method [18]. Data are presented as fold
change in mRNA expression between sarcoidosis patients
versus healthy controls. P-values were calculated using
two-tailed Student’s t-test of log2-transformed data (Prism
v6, GraphPad Software, La Jolla, CA).
BAL cytokine assays
We evaluated the protein expression of two candidate
genes identified from the microarray experiments, IL6
and CCL5 (RANTES), in BAL fluid of sarcoidosis and
control subjects using ultrasensitive kits (MesoScale
Discovery, Gaithersburg, MD) as per manufacturer’s
instructions. The plates were read using the MSD
Discovery workbench analyzer and software package.
Two groups of sarcoidosis patients were studied: 1)
subjects who also underwent microarray analysis of
their BAL cells (sarcoidosis 1, N = 15); 2) a validation
group of patients that were not part of the original
microarray study (sarcoidosis 2, N = 10). P-values were
calculated using the nonparametric, two-tailed Mann–
Whitney test because the cytokine data were not nor-
mally distributed based on Shapiro-Wilk’s normality
test (Prism v6, GraphPad Software, La Jolla, CA).
Results
Subject characteristics
Microarray analyses were conducted on BAL cells from
15 patients with pulmonary sarcoidosis and compared
with 12 healthy controls. Demographic data for each
subject is shown in Table 1. Both groups were
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predominantly African-American and female, and none
were active smokers. None of the healthy controls were
on medication and only two of the sarcoidosis patients
were on systemic steroids. All sarcoidosis subjects had
lung involvement with a majority having Scadding chest
radiograph stages 2 or 3. BAL cell differential counts in
both groups were predominantly macrophages, although
several sarcoidosis patients were characterized by signifi-
cant lymphocytosis. Detailed demographic information
is provided in Additional file 2: Table S1.
Sarcoidosis is associated with distinct transcriptional
profiles in BAL cells
Correspondence analysis of the entire microarray dataset
revealed that global variation in gene expression across
samples segregated sarcoidosis subjects from healthy
controls (Fig. 1). This finding implies that the transcrip-
tome of airspace cells is significantly altered in sarcoid-
osis. Using strict statistical criteria (FDR < 1 %), we
identified over 1500 differentially expressed transcripts
between the two groups (Fig. 2). Functional enrichment
of these genes revealed profound upregulation of many
processes involved in immunity and inflammation.
Sarcoidosis is characterized by activation of widespread
transcriptional programs
To obtain a more comprehensive and detailed survey of
activated pathways in patients with sarcoidosis, we
applied GSEA to the entire BAL cell microarray dataset.
We interrogated over 1300 manually curated canonical
pathways and identified 86 gene sets that were signifi-
cantly enriched in sarcoidosis (FDR < 1 %), but found no
significant enrichment in the control group (Additional
file 3: Table S2). This observation indicated that sarcoid-
osis is associated with upregulation of many distinct
pathways in BAL cells. We constructed a gene set en-
richment network whose members (nodes) were upregu-
lated pathways and their connectivity was based on
commonly shared genes (Fig. 3). We observed that func-
tionally similar pathways aggregated into larger groups
known as modules. There is increasing recognition that
biologic modules are critical drivers of disease suscepti-
bility and progression [19–21]. The most prominent
module associated with sarcoidosis was comprised of
multiple processes involved in immunity, with the lar-
gest pathway being “adaptive immune system” (Fig. 3).
Many of this module’s immunologic pathways have been
implicated in the pathogenesis of sarcoidosis including
aberrant T cell signaling, the IL17 pathway [22] as well
as IL12, IL27, and IL23 family of cytokines [23, 24].
Interestingly, natural killer (NK) cell cytotoxicity was
also a member of this module, and deficiency in NK cell
function has been linked to progression of sarcoidosis
[25–27].
Another large module was highlighted by cell cycle
and protein degradation processes, including the “prote-
asome” pathway (Fig. 3). The proteasomal system is a
protein-destroying apparatus that is critical for many
basic cellular functions such as cell cycle, differentiation,
apoptosis, and immune-related processes such as anti-
gen processing and presentation [28]. Most members of
the proteasome pathway were upregulated in patients
with sarcoidosis relative to control subjects (Fig. 4a) and
formed a tightly linked interactome based on network
analysis of experimentally verified, direct gene product
interaction databases (Fig. 4b). This analysis highlighted
the relationship between IFNG and several proteasomes
(e.g., PSMB8, PSMB9) that are integral components of
the immunoproteasome—the key proteolytic machinery
for MHC1 antigen presentation [29]. Indeed, as shown
in Fig. 3, the “proteasome” pathway is connected to
“adaptive immune system” indicating that these pro-
cesses share common genes and overlapping functions.
Collectively, these findings reveal that sarcoidosis alters
specific, highly interactive immune and proteasomal
pathways in BAL cells.
Comparative analysis of BAL cell transcriptome versus
lung tissue and circulating leukocyte gene expression
profiles in sarcoidosis
To extend and compare our findings to previous important
work in this field, we obtained publicly available microarray
Fig. 1 Correspondence analysis of transcriptional profiles between
sarcoidosis patients (magenta) and normal controls (cyan). Each axis
captures a proportion of the observed whole-genome expression
variability across all subjects. Note that this unbiased analysis segregated
the cohort into two groups based on disease status, implying that sar-
coidosis induces global changes in BAL cell transcriptome
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data from two published studies (http://www.ncbi.nlm.nih.-
gov/geo, GSE16538, GSE19314): 1) lung biopsy tissue from
patients with sarcoidosis (N = 6) and control subjects (N =
6) as reported by Crouser et al. [30]; 2) peripheral blood
leukocyte (PBL) gene expression in sarcoidosis (N = 38)
and healthy subjects (N = 20) from Koth et al. [31]. Both
studies used the Affymetrix Human GeneChip U133 Plus
2.0 microarray platform. We processed each dataset via the
same pipeline used for our BAL cell transcriptional ana-
lysis, including background adjustment and quantile
normalization using RMA followed by pathway analysis
with GSEA.
Using an FDR < 1 % cutoff to designate significant en-
richment, we identified 32 gene sets upregulated in lung
tissue and 47 gene sets upregulated in PBLs of patients
with sarcoidosis (Additional file 4: Table S3, Additional
file 5: Table S4). As summarized in Table 2, we found
broad functional overlap between BAL cell and lung tis-
sue pathway enrichment, but surprisingly few common
gene sets between either lung compartment (BAL cell,
tissue) versus circulating leukocytes in sarcoidosis pa-
tients. Our comparative analysis highlights a number of
potentially important messages. Firstly, GSEA of BAL
cells identified a substantially larger repertoire of acti-
vated pathways in sarcoidosis patients (N = 86 gene sets)
compared to lung tissue (N = 32) or PBLs (N = 47). This
finding suggests that airspace immune effector cells may
provide a more robust and consistent signal compared
to the more heterogeneous cell types obtained from lung
tissue biopsies or the lack of proximal association with
Fig. 2 Cluster analysis of differentially expressed genes in BAL cells between sarcoidosis patients and normal controls. Subject numbers
correspond to Table 1 descriptions. Significantly over-represented processes among differentially upregulated and downregulated genes in sarcoidosis
were identified using Gene Ontology (GO) annotation and are shown on the right panel
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involved end organ as is the case with circulating leuko-
cytes. Secondly, we found that in both BAL cells and
lung tissue biopsies of sarcoidosis patients, T cell-
associated gene sets were significantly upregulated but
in contrast, these pathways were downregulated in the
PBL dataset. While the implications of this observation
are not clear, the known critical role played by of activa-
tion of Th1 and T cell receptor signaling in the pathobi-
ology of sarcoidosis highlights the importance of
sampling cells from affected target organs to understand
mechanisms of disease pathogenesis. Finally, the enrich-
ment of the proteasome pathway in sarcoidosis was
found only in our BAL cell analysis. Given the import-
ance of this molecular machinery in modulating adaptive
immunity and thereby having a potentially novel role
in sarcoidosis, our approach of interrogating immune
effector cells in the airspaces shows promise for helping
unravel previously unrecognized processes in this com-
plex disease.
Confirmation of select candidate genes
We assessed whether the immuno-inflammatory signal
observed in BAL cells of patients with sarcoidosis was
also present in their BAL fluid by measuring protein
levels of two differentially upregulated genes: IL6 and
CCL5. As shown in Fig. 5, BAL fluid levels of both cyto-
kines were significantly elevated in the initial cohort
of patients from the microarray study (sarcoidosis 1,
N = 15) as well as an independent group of subjects with
sarcoidosis (sarcoidosis 2, N = 10). Subject characteristics
of the independent sarcoidosis group are available at
Additional file 6: Table S5. Since our computational
Fig. 3 Integrative network analysis of enriched pathways in sarcoidosis as identified using GSEA. A gene set was considered enriched for a given
phenotype if most of its member genes were upregulated in that condition. 83 gene sets were upregulated in patients with sarcoidosis whereas
very few pathways were enriched in the controls (not shown). In the figure, each sphere designates an enriched pathway in sarcoidosis and the
size of each sphere (i.e., gene set) is proportional to the number of its gene members. Only a selected number of pathways have been labeled
due to space restriction, but full list is available at Additional file 3: Table S2. Since pathways can share common genes, connectivity lines have
been drawn to link these inter-pathway relationships and define the topology of the enrichment network by identifying larger aggregates of
functionally associated pathways known as modules. The most prominent module associated with sarcoidosis was “immunity” and incorporated
T-cell signaling (T helper and CD8), graft vs. host disease, IL12, IL23, and IL17 pathways among others, but also note the presence of other
modules such as “oxidative phosphorylation” and “cell cycle/protein degradation”. Importantly, some pathways from different modules were also
linked together, such as the inter-modular connectivity of “adaptive immune system” with “proteasome” as shown in the figure. This relationship
indicates that these two gene sets share common functional characteristics and implicates proteasomal processes as potential modulators of
adaptive immunity in sarcoidosis
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analyses associated the activation of proteasome pathway
with adaptive immunity, we validated the differential up-
regulation of two important immunoproteasomes
(PSMB8, PSMB9) as well as IFNG, the critical link be-
tween immune response and proteasomal apparatus, in
BAL cells using qPCR (Fig. 6).
Discussion
The etiology of sarcoidosis continues to be debated, with
much investigation into potential instigators of the ob-
served exaggerated and aberrant immune response.
Since the lung is the most common site of organ in-
volvement, we hypothesized that investigating the air-
space immune cell transcriptome would provide insight
into disease pathogenesis and reveal putative novel
therapeutic targets.
We compared the transcriptional profiles of lung BAL
cells in sarcoidosis patients versus control subjects and
found significant differences between the two groups,
most prominently the selective enrichment of distinct
immune-related pathways. As confirmation of our un-
biased approach, we identified a number of immune
modulators previously implicated in sarcoidosis, includ-
ing IFNG [32], IL12 [23], and IL17 [22]. Notably, in
addition to observing enrichment of T helper cell signal-
ing that is well-described in sarcoidosis [33], we also
found strong signals from CD8/T cell receptor pathways,
potentially implicating a role for autoimmune T cells in
sustaining inflammatory responses and contributing to
the pathogenesis of this complex disease [34].
Our data are consistent with studies of whole blood and
lung tissue transcriptome which demonstrated upregula-
tion of interferon signaling and activation of immuno-
inflammatory pathways [30–32, 35]. Similarly, some of
our findings overlap with gene expression analysis of sar-
coidosis skin lesions that also showed involvement of IL23
and IL17 signaling [36]. Collectively, these studies outline
a system-wide transcriptional signature associated with
sarcoidosis that may be useful for diagnostic purposes.
However, we also found significant differences in gene set
enrichment across different compartments (BAL cell, lung
tissue, circulating leukocytes) consistent with the concept
that host response in sarcoidosis is cell-type and organ
specific.
By integrating pathway and network analysis of BAL cell
expression profiles, we constructed a modular overview of
differentially activated processes in sarcoidosis that linked
key putative drivers of disease. In particular, our analysis
highlighted a potentially important connection between
adaptive immunity and the proteasomal apparatus. The
proteasome is part of the ubiquitin-proteasome system,
which controls intracellular protein degradation and
Fig. 4 Heatmap display (a) and gene product interaction network (b) of the enriched proteasome pathway in sarcoidosis. Subject numbers
correspond to Table 1 descriptions. Note the prominent role of IFNG in integrating key immunoproteasome components, such as PSMB8
and PSMB9
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turnover. Activation of proteasome complex components
suggests that sarcoidosis induces a proteolytic environ-
ment for substrate degradation. We found upregulation of
constitutive proteasome catalytic subunits and the
inducible proteasome subunits, PSMB8, PSMB9 and
PSMB10. The inducible subunits form the immunopro-
teasome, which is upregulated by oxidative stress and
proinflammatory cytokines, particularly IFNG [37]. Key
functions of the immunoproteasome are processing
class I MHC peptides and regulation of inflammation,
which are of particular relevance to the pathogenesis of
sarcoidosis. The immunoproteasome regulates inflam-
matory responses through the activation of NFkB, which
then induces expression of proinflammatory cytokines
such as tumor necrosis factor (TNF), interleukin 1 beta
(IL1B), and interleukin 8 (IL8) [38]. The proteasome
machinery can also proteolyze cyclins which impacts
Table 2 Summary of common and discordant enrichment of
pathways between BAL cell, lung tissue and PBLs in subjects
with sarcoidosis
Selective list of pathways upregulated in both BAL cell and lung tissue
biopsies of sarcoidosis patients
Graft vs. host disease
T cell receptor signaling
Allograft rejection
Primary immunodeficiency
Natural killer cell mediated cytotoxicity
Csk pathway (activation of Csk by cAMP-dependent protein kinase
inhibits signaling through T cell receptor)
Immunoregulatory interaction between lymphoid and non lymphoid cell
IL12 pathway
TCRA pathway (Lck and Fyn tyrosine kinases in initiation of T cell
receptor activation)
Th1 Th2 pathway
CTL pathway (cytotoxic T lymphocyte mediated immune response
against target cells)
NKT (natural killer T cell) pathway
Autoimmune thyroid disease
CTLA4 (cytotoxic T-lymphocyte-associated protein 4) pathway
PD-1 (programmed death-1) signaling
Type 1 diabetes mellitus
Pathways upregulated in both BAL cell and PBLs of sarcoidosis patients
Antigen processing cross presentation
RIP (receptor-interacting protein)-mediated NFkB activation via DAI
(DNA-dependent activator of interferon)
Pathways upregulated in BAL cell and lung tissue but downregulated in
PBLs of sarcoidosis patients
T cell receptor pathway
Csk pathway (activation of Csk by cAMP-dependent protein kinase
inhibits signaling through T cell receptor)
TCRA pathway (Lck and Fyn tyrosine kinases in initiation of T cell
receptor activation)
CTLA4 (cytotoxic T-lymphocyte-associated protein 4) pathway
Fig. 5 BAL levels of IL6 (a) and CCL5 (b) are elevated in sarcoidosis
patients. Cell-free bronchoalveolar fluid (BALF) was analyzed by
Mesoscale Discovery in normal controls (N = 12), sarcoidosis subjects
who underwent the microarray analysis of their BAL cells (sarcoidosis
1, N = 15) and a validation group of sarcoidosis patients that were
not part of the original microarray study (sarcoidosis 2, N = 10). P-
values were calculated using two-tailed Mann–Whitney test
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the inflammatory responses through regulation of leukocyte
proliferation [39]. Consistent with this role, our modular
enrichment network demonstrated tight linkage between
the proteasome and cell cycle regulators.
Our findings are consistent with a recent report by
Sixt et al. [40], who found significantly higher levels of
extracellular BAL proteasome activity in sarcoidosis
patients. They demonstrated increased immunoreac-
tivity of PSMB8 and PSMB9 in sarcoidosis lungs, pri-
marily in epithelial cells and granulomas [40]. Our
data confirm and expand their findings by showing
that multiple components of proteasome are upregu-
lated in the lung immune effector cells and that these
processes may be linked to immune and cell cycle
pathways via specific network hubs such as IFNG.
While prior transcriptomic studies of lung tissue and
blood did not identify enrichment of proteasome com-
ponents, all reported upregulation of IFNG, a key
regulator of the immunoproteasome [30–32, 35]. Im-
portantly, proteasomal pathways are high priority tar-
gets for a new class of therapeutic drugs in a variety of
diseases including cancer, neurodegenerative disor-
ders, and autoimmune diseases [41–43]. Future work
is needed to assess the intriguing possibility that these
drugs may be effective for treatment of sarcoidosis.
Our study has a number of limitations. Since the num-
ber of subjects was relatively small, our analyses should be
considered exploratory and require confirmation in larger
cohorts. However, our sample size was similar to previous
reports leveraging tissue gene expression profiling to elu-
cidate disease mechanisms in sarcoidosis [30, 36]. Since
only two patients were on systemic steroids, we were un-
able to determine an effect of therapy on gene expression
signatures. Our study was cross-sectional, therefore longi-
tudinal follow-up studies are needed to establish whether
any of the transcriptional signatures correlate with dis-
ease progression. There was significant heterogeneity
among the sarcoidosis patients, however, we did not ob-
serve distinct segregation based on race or disease se-
verity when applying cluster analysis to the BAL cell
expression data. Furthermore, a number of the sarcoid-
osis patients undergoing gene expression analysis were
former smokers, a potential confounding environmental
exposure [44]. Although we did not separate out the dif-
ferent lung cell populations, the most dominant cell
type in the subject cohort was alveolar macrophages.
However, several sarcoidosis patients also had lympho-
cytosis and these cells likely contributed to overall gene
expression. Nevertheless, we did not observe segrega-
tion of sarcoidosis patients based on their relative BAL
lymphocyte or macrophage counts when applying clus-
ter analysis (Fig. 2), suggesting that variability in cell
count percentages did not heavily influence the overall
transcriptional signal. Future studies investigating cell-
specific gene expression of BAL cells (e.g., lymphocytes
and macrophages) will be important to further delineate
the selective role of immune cell subtypes in sarcoidosis.
By design, all study patients had pulmonary sarcoidosis.
It will be of interest to determine whether the lung cell
transcriptome in sarcoidosis patients without overt lung
involvement has similar expression patterns. Our com-
parative analysis using available gene expression profiles
from other tissues and compartments supports this con-
cept and suggests that sarcoidosis is associated with per-
turbation in a common core of pathways spanning
target end organs.
Conclusion
We have outlined a systematic framework to investigate
the role of airspace immune cells in the pathogenesis of
Fig. 6 Immunoproteasome components are overexpressed in BAL cells from patients with sarcoidosis. PSMB8, PSMB9, and IFNG gene expression
levels were determined by qPCR from RNA isolated from BAL cells of normal controls and sarcoidosis patients. RNA expression was normalized to
GAPDH as described in Methods section. Data are presented as Log2 [fold change] in mRNA expression between sarcoidosis patients versus
control subjects. P-values were calculated using two-tailed Student’s t-test of log2-transformed data
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sarcoidosis. We found that this complex disease is associ-
ated with the activation of diverse yet distinct pathways
and identified key members of the proteasome apparatus
as potential modulators of host immune response. Future
work is required to further delineate these relationships
and determine their influence in disease progression.
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